REGN in the 13F filings
Regeneron Pharmaceuticals · CUSIP 75886F107
- Quarter end
- 31 Dec 2025
- the date the book describes
- Filed
- 27 Oct 2026
- latest of these filings; the earliest 5 Feb 2026
- Managers listing it
- 40
- at least, of 95 tracked, among listed positions
- Comparable managers
- 92
- filed both Q3 2025 and Q4 2025; 31 listed it in both
- Shares listed
- 21,401,177
- combined, among listed positions
- Reported value
- $16.5bn
- combined, at the quarter end
Among the 92 comparable managers: 20 buyers (opened or added shares) and 23 sellers (trimmed or exited), at least, among listed positions. Their net change in shares was +2,784,775.
Managers listing REGN in Q4 2025
40 of 40 holders
Largest increases and reductions, by shares
Increases
- Invesco Ltdexisting position · 3,911,496 shares now+2,427,023
- T. Rowe Price Associates Incexisting position · 1,949,797 shares now+1,144,887
- Wellington Management Group LLPexisting position · 664,465 shares now+656,845
- Fidelity (FMR LLC)existing position · 2,319,566 shares now+383,731
- Holocene Advisors LPexisting position · 460,723 shares now+308,990
Reductions
- D. E. Shaw & Co.existing position · 155,475 shares now-706,118
- Capital World Investorsexisting position · 1,398,003 shares now-600,363
- Two Sigma Advisers LPexisting position · 604,540 shares now-321,660
- Renaissance Technologies LLCexisting position · 9,082 shares now-266,080
- Two Sigma Investments LPexisting position · 281,151 shares now-188,752
New positions and exits
New (1)
Exited (3)
- Voloridge Investment Management LLCwas $97m
- Schonfeld Strategic Advisors LLCwas $1.5m
- Quantbot Technologies LPwas $228k
Ownership over time
Tracked managers listing it, at least.
| Quarter | Holders | Reported value | Buyers | Sellers |
|---|---|---|---|---|
| Q2 2013 | 20 | $8.0bn | n.a. | n.a. |
| Q3 2013 | 19 | $10.8bn | n.a. | n.a. |
| Q4 2013 | 17 | $8.9bn | n.a. | n.a. |
| Q1 2014 | 18 | $8.8bn | n.a. | n.a. |
| Q2 2014 | 20 | $8.4bn | n.a. | n.a. |
| Q3 2014 | 22 | $10.7bn | n.a. | n.a. |
| Q4 2014 | 16 | $12.3bn | n.a. | n.a. |
| Q1 2015 | 18 | $13.2bn | n.a. | n.a. |
| Q2 2015 | 16 | $14.7bn | n.a. | n.a. |
| Q3 2015 | 21 | $12.9bn | n.a. | n.a. |
| Q4 2015 | 20 | $15.3bn | n.a. | n.a. |
| Q1 2016 | 24 | $11.3bn | n.a. | n.a. |
| Q2 2016 | 20 | $10.5bn | n.a. | n.a. |
| Q3 2016 | 18 | $12.0bn | n.a. | n.a. |
| Q4 2016 | 22 | $10.4bn | n.a. | n.a. |
| Q1 2017 | 18 | $10.3bn | n.a. | n.a. |
| Q2 2017 | 23 | $13.6bn | n.a. | n.a. |
| Q3 2017 | 21 | $11.6bn | n.a. | n.a. |
| Q4 2017 | 27 | $9.4bn | n.a. | n.a. |
| Q1 2018 | 27 | $8.5bn | n.a. | n.a. |
| Q2 2018 | 24 | $9.2bn | n.a. | n.a. |
| Q3 2018 | 27 | $10.8bn | n.a. | n.a. |
| Q4 2018 | 28 | $9.9bn | n.a. | n.a. |
| Q1 2019 | 28 | $10.4bn | n.a. | n.a. |
| Q2 2019 | 29 | $8.3bn | n.a. | n.a. |
| Q3 2019 | 24 | $7.1bn | n.a. | n.a. |
| Q4 2019 | 18 | $9.0bn | n.a. | n.a. |
| Q1 2020 | 27 | $13.0bn | n.a. | n.a. |
| Q2 2020 | 23 | $19.8bn | n.a. | n.a. |
| Q3 2020 | 24 | $17.4bn | n.a. | n.a. |
| Q4 2020 | 26 | $15.2bn | n.a. | n.a. |
| Q1 2021 | 22 | $13.7bn | n.a. | n.a. |
| Q2 2021 | 27 | $15.3bn | n.a. | n.a. |
| Q3 2021 | 26 | $15.5bn | n.a. | n.a. |
| Q4 2021 | 28 | $16.3bn | n.a. | n.a. |
| Q1 2022 | 25 | $19.2bn | n.a. | n.a. |
| Q2 2022 | 26 | $16.5bn | n.a. | n.a. |
| Q3 2022 | 24 | $19.0bn | n.a. | n.a. |
| Q4 2022 | 30 | $20.2bn | n.a. | n.a. |
| Q1 2023 | 32 | $22.3bn | n.a. | n.a. |
| Q2 2023 | 28 | $18.8bn | n.a. | n.a. |
| Q3 2023 | 26 | $21.1bn | n.a. | n.a. |
| Q4 2023 | 35 | $21.9bn | 22 | 14 |
| Q1 2024 | 28 | $23.6bn | 12 | 20 |
| Q2 2024 | 28 | $25.6bn | 15 | 15 |
| Q3 2024 | 31 | $25.0bn | 17 | 15 |
| Q4 2024 | 27 | $13.8bn | 17 | 12 |
| Q1 2025 | 29 | $12.2bn | 20 | 10 |
| Q2 2025 | 32 | $9.3bn | 24 | 10 |
| Q3 2025 | 33 | $10.1bn | 22 | 12 |
| Q4 2025 | 33 | $16.3bn | 20 | 23 |
| Q1 2026 | 24 | $15.2bn | 14 | 26 |
| Q2 2026 | 22 | $10.6bn | 24 | 15 |
Compare with…
Holders over time, buyers and sellers, and the managers holding both, side by side for up to four stocks.
REGN and LLY →REGN and JNJ →REGN and VRTX →Choose a stock to compare with REGN →
How much of the picture this is
A 13F is a manager’s long US-listed equity book at a quarter end, filed up to 45 days later. It shows no shorts, cash, bonds or performance, and it is never today’s portfolio. Large books are listed to their largest positions, so a manager missing from this table may still hold a small position below that line. These are 95 tracked managers, not the institutional market.
Which funds own REGN, latest filings →Back to the 13F Explorer →